HTDDSFMT · HIGH THROUGHPUT DRUG DISCOVERY STUDIESFOR MENINGIOMA THERAPEUTICS
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2011-08-01 → 2015-07-31
- Финансиране от ЕС
- 100 000 €
- Участници
- 1
- Схема
- MC-CIG
Линиите свързват координатора с партньорите.
Накратко на български
Лекарства за лечение на менингиоми (тумори на мозъчните обвивки) се търсят чрез високопроизводителни скринингови методи. Това помага за откриването на по-ефективни терапии за пациентите с този вид онкологични заболявания.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
HIGH THROUGHPUT DRUG DISCOVERY STUDIES FOR MENINGIOMA THERAPEUTICS
SUMMARY In the last four years getting support from the CIG grant and other sources, we have got several significant achievements in the current and as well as the other projects that are running in our research unit. This can be summarized as follows: 1. Molecular Neuro-Oncology Research Unit: As mentioned in the first period reporting that we have established the Molecular Neuro-Oncology Research Unit within the Department of Pediatrics in Medical University of Vienna. The unit is currently having several national and international research activities with highly prestigious research institutions from Harvard Medical School (USA), the Amsterdam Cancer Center (the Netherlands), to Hacettepe University (Turkey). Based on these collaborations, several research activities have been initiated and in part, completed. Please see publication list. 2. Academic Career and Teaching Activities I am currently serving as “Director” of the research unit, and became a Tenured Associate Professor in May 2015 at the Medical University of Vienna. Two PhD students and 2 MD diploma students have been graduated under my supervision. We have currently two postdocs and 2 PhD and 4 diploma students. I am also involved in teaching activities at the university. So far, I organized five lectures (Journal Clubs and Thesis seminar) during grant period. 3. Professional Memberships: I also become an Associate member of the “American Society of Gene & Cell Therapy” and International Society for Extracellular Vesicles (ISEV). I have been also served as Chair, and/or a speaker in some of the meeting organized by these societies. 4. Current Grants (Direct costs): 2011-2015 EU-FP7-PEOPLE-2011-CIG, Austria Okay Saydam (PI) 2010-2015 Melodie Stiftung Saydam (PI), ~ 900,000 USD 2010-2015 Forschungsgesellschaft for Brain Tumors Saydam (PI), ~ 250,000 USD 2013-2016 CHILDREN'S CANCER RESEARCH INSTITUTE, CCRI-0017 Saydam (PI), ~ 350,000 USD 2015-2017 LKW Bauers, Saydam (PI) 60,000 USD 2015-2017 Scientific-Technical Agreement with Ukraine-Austria Saydam (PI), 25,000 USD Pending 1. Extracellular Vesicle/Serum-Based Tumor Biomarker Screening Studies For Glioblastomas (Saydam PI). KLIF, FWF: ~ 500,000 USD 2. Long noncoding RNAs in medulloblastoma tumorigenesis. (Saydam PI). ONB, ~ 250,000 USD
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Meningiomas arise from arachnoid cells and account for approximately 30% of all primary intracranial tumors. Most meningiomas (80-90%) are categorized as benign tumors (WHO grade I), with the remaining 10-20% being atypical (WHO grade II) or malignant (WHO grade III). Gross total resection offers the best chance of cure. Unfortunately, for meningiomas that are difficult to access, complete resection often cannot be achieved safely. In patients whose tumors are incompletely resected, recurrence is common, approaching 70% with 10–15 years of follow-up; in the case of atypical and malignant meningiomas, the time to recurrence is shorter and long-term survival rates are low. There are no established treatments for recurrent meningioma when surgical and radiation options are exhausted and current experience with chemotherapy and various targeted therapies is disappointing. Therefore, novel therapeutic strategies which can be combined with surgery need to be developed to control tumor growth. This application is directed towards developing new therapeutic options for meningiomas in a high throughput small (HTS) molecule screening system using the NINDS custom collection II library consisting of 1040 drugs and bioactive compounds, FDA-approved, which cross the blood-brain barrier (BBB). In our primary screening, we identified drug candidates that were specifically toxic to meningioma cells. These promising preliminary data stimulate us to further evaluate the effect of these candidates on meningioma tumor models in mice and explore the possible molecular mechanism(s) of tumor inhibition mediated by these candidate drugs.
Оригинален текст от CORDIS (на английски).
Участници
- MEDIZINISCHE UNIVERSITAET WIEN · WienКоординаторАвстрия
Връзки
Данни: CORDIS, © Европейски съюз